Isabella Capodanno

Reggio Nell'emilia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 09, 2026

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.

Journal: European journal of haematology

Published: February 24, 2026

Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study.

Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study.

Journal: Annals of hematology

Published: January 31, 2026

An Italian cartography of VEXAS-related thrombosis.

An Italian cartography of VEXAS-related thrombosis.

Journal: HemaSphere

Published: January 17, 2026

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Journal: Cancer

Published: November 16, 2025

Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.

Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.

Journal: British journal of haematology

Published: September 03, 2025

The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.

The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.

Journal: Frontiers in oncology

Published: June 11, 2025

Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.

Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.

Journal: Cancer

Published: May 12, 2025

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Journal: Cancers

Published: March 28, 2025

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.

Journal: Hematological oncology

Published: March 24, 2025

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Journal: Leukemia

Published: March 04, 2025

Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.

Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.

Journal: Cancer

Published: February 23, 2025

Showing 1-12 of 61

Last Updated: 09/26/2026